
Herbalife (HLF) has been in focus after analysts raised full year earnings estimates, a shift in expectations that has coincided with the stock’s solid year to date gain and its outperformance compared with its sector.
See our latest analysis for Herbalife.
At a share price of $15.29, Herbalife’s year to date share price return of 19.27% and 1 year total shareholder return of 80.95% point to building momentum, even with a recent 7 day share price pullback of 8.44%.
If you are weighing Herbalife’s move against other opportunities, this is a good moment to see how it stacks up beside 20 top founder-led companies
With Herbalife trading at $15.29, showing a 50% intrinsic discount estimate and still sitting below the average analyst price target, investors may ask whether there is still value on the table or whether the market is already pricing in future growth.
With Herbalife last closing at $15.29 against a narrative fair value of $14.00, the current price sits slightly above that central estimate, setting up a debate around how far the turnaround story can go.
Recent research on Herbalife reflects a mix of optimism about the company’s turnaround efforts and caution about broader sector and macro headwinds. Price targets in the research set range from US$11 to US$20, with differing views on how much of the potential recovery is already reflected in the current valuation.
Analysts are incorporating a recovery built on healthier profit margins, a lower discount rate, and improving cash generation, while still tempering revenue expectations and valuation multiples. This raises the question of which assumptions matter most and how they add up to that $14 fair value and a very large forecast return on equity.
Result: Fair Value of $14 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that recovery path could still be upset if regulatory scrutiny of the multi level marketing model tightens further, or if consumer preference shifts away from processed supplements accelerate.
Find out about the key risks to this Herbalife narrative.
While the narrative fair value of $14 suggests Herbalife is 9.2% overvalued, the current P/E of 6.9x tells a different story. It sits well below the estimated fair ratio of 13.9x, the Global Personal Products average of 20.2x, and a 68.9x peer average. This raises the question of whether sentiment has swung too far.
See what the numbers say about this price — find out in our valuation breakdown.
With sentiment clearly split between caution and optimism, this is a good time to check the numbers yourself and decide where you stand, starting with 3 key rewards and 2 important warning signs
If Herbalife has caught your attention, do not stop here. Use this momentum to scan for other opportunities that could fit your portfolio before others move first.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com